Ziprasidone: a novel psychotropic with unique properties

References

• Miceli JJ, Hunt T, Cole MJ et al The pharmacokinetics (PK) of CP 88,059 (CP) in healthy male volunteers following oral (P0) and intravenous (IV) administration. Clin. Pharmacol Ther. 55, 142 (1994).
   Google Scholar
• Miceli JJ, Wilner KD, Hansen, RA et al. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. BE j Gun. Phatmacol 49, 5–15 (2000).
   PubMed Web of Science ®Google Scholar
• Wilner KD, Tensfeldt TG, Bans B et al Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. BE j Gun. Pharmacol 49, 15–20 (2000)
   Web of Science ®Google Scholar
• Everson G, Lasseter KC, Anderson KE et al The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. BE j Clin. Phatmacol 49, 21–26 (2000).
   PubMed Web of Science ®Google Scholar
• Aweeka F, Jayesekara D, Horton M et al The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. BE Clin. Pharmacol 49, 27–33 (2000).
   PubMed Web of Science ®Google Scholar
• Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J. Clin. fiychopharmacol 23,229–232 (2003).
   PubMed Web of Science ®Google Scholar
• •An elaboration of ziprasidone's metabolism and the relevant clinical sequelae.
   Google Scholar
• Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. BE Clin. Phalmacol 49, 35–42 (2000).
   Google Scholar
• Miceli JJ, Smith M, Robarge L, Morse T, Laurent A. The effects of ketoconazole on ziprasidone pharmacokinetics — a placebo-controlled crossover study in healthy volunteers BE j Clin. Pharmacol 49, 71–76 (2000).
   Google Scholar
• Wilner KD, Hansen RA, Folger CJ, Geoffroy, P The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. BE j Clin. Pharmacol 49,57–60 (2000).
   Web of Science ®Google Scholar
• Muirhead GJ, Harness J, Holt PR, Oliver S, Anziano RJ. Ziprasidone and the pharmacokinetics of a combined oral contraceptive. BE J. Clin. Pharmacol 49, 49–56 (2000).
   Google Scholar
• Wilner KD, Demattos SB, Anziano RJ, Apseloff G, Gerber N. Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. BE j Clin. Pharmacol 49, 43–47 (2000).
   Google Scholar
• Apseloff G, Mullet D, Wilner KD et al. The effects of ziprasidone on steady state lithium levels and renal clearance of lithium Br.Clin. Phalmacol 49,61–64 (2000).
   Google Scholar
• Seeger TF, Seymour PA, Schmidt AW et al. Ziprasidone (CP-88,059), a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Pharmacol Experiment. Ther. 275, 101–113 (1995).
   Google Scholar
• Richelson E, Souder T Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci. 68,29–39 (2000).
   PubMed Web of Science ®Google Scholar
• Schmidt AW, Lebel LA, Howard HR et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur j Pharmacol 425,197–201 (2001).
   PubMed Web of Science ®Google Scholar
• Bench CJ, Lammertsma AA, Dolan RJ et al Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C—raclopride. Bychopharmacology112, 308–314 (1993).
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci. 68,29–39 (2000).
   PubMed Web of Science ®Google Scholar
• Altar CA, Wasley AM, Neale RF et al. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res. Bull. 16,517-525 (1986).
   Google Scholar
• Rollema H, Schmidt AW, Sprouse JS et al. 5-HT1A receptor activation contributes to ziprasidone-influenced dopamine release in the rat prefrontal cortex. Biological Psych. 48,229–237 (2000).
   Web of Science ®Google Scholar
• Murray S, Siu Co, Romano SJ. Optimal dosing of oral ziprasidone: analysis of clinical trial data Poster presented at Annual Meeting of the American Psychiatric Association, CA, USA. 17–22 May (2003).
   Google Scholar
• Hirsch SR, Kissling W Bauml J, Power A, O'Connor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. j Clin. Psych. 63(6), 516–523 (2002).
   Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Aiumpsychophalmacology20(5), 491–505 (1999).
   Google Scholar
• Addington D, Pantelis C, Dineen M, Benattia M, Romano SJ, Murray S. Ziprasidone vs. risperidone in schizophrenia: 52 weeks' comparative data. Presented at the Annual Meeting of the American Psychiatric Association, CA, USA. 17–22 May (2003).
   Google Scholar
• Arato M, O'Connor R, Meltzer HY, ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int. Clin. PTchopharmacol 17(5), 207–215 (2002).
   Google Scholar
• ••The major clinical trial detailing ziprasidone's efficacy and side effects.
   Google Scholar
• Keck PE Jr, Reeves KR, Harrigan EP, Ziprasidone Study Group. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J. Clin. PTchophannacol 21(1), 27–35 (2001).
   Google Scholar
• •Represents the major study of ziprasidone in the treatment of schizoaffective disorder.
   Google Scholar
• Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J. Clin. Psych. 64(5), 580–588 (2003).
   Google Scholar
• Kaye NS. Ziprasidone augmentation of clozapine in 11 patients. j Clin. Psych. 64(2), 215–216 (2003).
   Google Scholar
• Geodon Package Insert. June (2002).
   Google Scholar
• Glick ID, Romano SJ, Simpson G et al. Insulin resistance in olanzapine and ziprasidone treated patients: results of a double-blind, controlled 6 week trial. Presented at the Annual Meeting- of the American PTchiatric Association, LA, USA. 5–10 May (2001).
   Google Scholar
• Cohen S, Fitzgerald B, Okos A, Khan S, Khan A. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J. Clin. Psych. 64(1), 60–62 (2003).
   Google Scholar
• Carnahan RM, Lund BC, Perry PJ. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy21 (6), 717–730 (2001).
   PubMed Web of Science ®Google Scholar
• Micell JJ, Shiovitz T, Swift RII, Anziano RJ, Tensfeldt T High-dose ziprasidone is associated with marginal additional QTC increase. Presented at the Annual Meeting of the American Psychiatric Association, CA, USA. 17–22 May (2003).
   Google Scholar
• Biswas AK, Zabrocki LA, Mayes KL, Morris-Kukoski CL. Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. J. Toxicol Clin. Toxicol 41(2), 101–104 (2003).
   Google Scholar
• Baldassano CF, Ballas C, Datto SM et al. Ziprasidone-associated mania: a case series and review of the mechanism. Bipolar Dis. 5(1), 72–75 (2003).
   Google Scholar
• Nolan BP, Schulte JJ Jr. Mania associated with initiation of ziprasidone. j Clin. Psych. 64(3), 336 (2003).
   Google Scholar
• Lu BY, Lundgren R, Escalona PR, Roberts BB. A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics. j Clin. Psych. 63(12), 1185–1186 (2002).
   Google Scholar
• Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am .j Psych. 160(4), 741–748 (2003).
   Google Scholar
• ••Investigates the efficacy of ziprasidone in the treatment of acute mania. It indicates that doses of more than 120 mg/day may be needed for a robust clinical effect.
   Google Scholar
• Kennedy SH, Lam RVV. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disonl 5\(Suppl. 2), 36–47 (2003).
   Google Scholar
• Shelton RC, Tollefson GD, Tohen M et al A novel augmentation strategy for treating resistant major depression. Am J: Psych. 158(1), 131–134 (2001).
   Google Scholar
• McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J: Am. Acad. Child Adolesc. Psych. 41(8), 921–927 (2002).
   Google Scholar
• Cohen S, Firtzgerald B, Okos A, Khan S, Khan A. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J: Cliii Psych. 64(1), 60–62 (2003).
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am.j Psych. 158(3), 360–369 (2001).
   Google Scholar
• ••Important paper in the future ofpsychopharmacology. It suggests that the relevant factors in antipsychotic efficacy extrapyramidol symptoms are dissociation rates from the D2 receptor. Furthermore, it suggests that all other notions (i.e. serotonergic system) do not reflect the reality of lower extrapyramidal symptom rates.
   Google Scholar
• Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J. Psychopharmacol 23(6), 595–600 (2003).
   Web of Science ®Google Scholar